"We are pleased that the STEP trial of Progenza for knee osteoarthritis is on track to report results in Q4 FY17, following years of hard work by our research and development team in getting us to this stage. We have previously reported that there was a positive interim safety review for both dose cohorts. These results will be an important addition to our clinical partnering discussions in Japan."
RGS Price at posting:
15.0¢ Sentiment: Hold Disclosure: Not Held
